Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Appointed director
SELLAS Life Sciences Group, Inc. (SLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results"
05/11/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results"
03/16/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update"
11/14/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/12/2021 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update"
03/23/2021 8-K Quarterly results
11/13/2020 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results - Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia patients -"
08/13/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
05/15/2019 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results Company to Present Data at Upcoming American Society of Clinical Oncology Annual Meeting"
03/22/2019 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update , March 22, 2019 - SELLAS Life Sciences Group, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today reported financial results for the year ended December 31, 2018 and provided a business update. “In February, we initiated a review of a wide range of strategic alternatives to maximize shareholder value, such as a sale of the Company, a merger, or a strategic investment or financing,” stated Dr. Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS. “We are currently actively exploring these alternatives with the goal of identifying a plan that will enhance shareholder value whil..."
11/15/2018 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results Conference call today at 8:00 a.m. ET"
04/16/2018 8-K Quarterly results
Docs: "FORM 8-K",
"SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results , April 16, 2018 - SELLAS Life Sciences Group Inc. , a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today reported financial results for the year ended December 31, 2017 and provided a business update. “In recent months, we have made meaningful progress advancing our business objectives, maturing SELLAS Life Sciences Group Ltd. into a publicly-traded company following the business combination and progressing our pipeline of cancer immunotherapies for patients with limited treatment options,” said Angelos Stergiou, MD, ScD h.c., President & Chief Executive Officer of SELLAS. “We are parti..."
11/09/2017 8-K Quarterly results
Docs: "Galena Biopharma Reports Third Quarter 2017 Financial Results"
08/14/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update",
"Therapeutic Area Phase 1 Phase 2 Phase 3 BLA"
05/10/2016 8-K Quarterly results
Docs: "Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update",
"PHASE 3 PRESENT TRIAL PER SPA 1 2 3 4"
11/09/2015 8-K Quarterly results
Docs: "Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on its Clinical Development Programs with Planned Divestiture of the Commercial Business • Clinical development immunotherapy programs make significant advances with new trials including a NeuVax™ Phase 2 clinical trial in DCIS and encouraging Phase 2a data for GALE-301 • Commercial operations and products, Abstral® Sublingual Tablets and Zuplenz® Oral Soluble to be divested • Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.",
"CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS"
08/06/2015 8-K Quarterly results
Docs: "Galena Biopharma Reports Second Quarter 2015 Financial Results",
"FORWARD LOOKING STATEMENT This"
05/07/2015 8-K Quarterly results
Docs: "Galena Biopharma Reports First Quarter 2015 Financial Results"
03/05/2015 8-K Quarterly results
Docs: "Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results • Cancer immunotherapy programs - NeuVax™ and GALE-301 - made significant advancements in 2014 ▪ Achievement of key milestones anticipated in 2015 including completion of enrollment in NeuVax Phase 3 PRESENT trial • Commercial strategy validated as revenue continues to increase ahead of second commercial launch ▪ Abstral® Sublingual Tablets 2014 net revenue hits guidance range with $9.3 million; 2015 net revenue guidance reiterated at $15-$18 million • Conference call and webcast scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T. Portland, Oregon, March 5, 2015 - Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that ..."
11/03/2014 8-K Quarterly results
Docs: "EXHIBIT"
08/11/2014 8-K Quarterly results
Docs: "EXHIBIT"
05/06/2014 8-K Quarterly results
Docs: "EXHIBIT"
03/17/2014 8-K Quarterly results
Docs: "EXHIBIT"
11/06/2013 8-K Quarterly results
Docs: "Galena Biopharma Reports Third Quarter 2013 Results Portland, Oregon, November 6, 2013— Galena Biopharma , a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today reported its financial results for the three and nine months ended September 30, 2013 and provided a business update. “Our commercial success to date with Abstral ® has been very encouraging and we are excited to report initial revenues ahead of schedule. With our sales force and commercial organization fully deployed, we continue to make significant strides with physicians, payors and patients — and expect continuing strength with the launch,” said Mark J. Ahn, Ph.D., President and Chief Executive Officer. “We are als..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy